Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
- PMID: 23412562
- PMCID: PMC3590398
- DOI: 10.1007/s00277-013-1698-0
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Abstract
Bacterial infections are the most common cause for treatment-related mortality in patients with neutropenia after chemotherapy. Here, we discuss the use of antibacterial prophylaxis against bacteria and Pneumocystis pneumonia (PCP) in neutropenic cancer patients and offer guidance towards the choice of drug. A literature search was performed to screen all articles published between September 2000 and January 2012 on antibiotic prophylaxis in neutropenic cancer patients. The authors assembled original reports and meta-analysis from the literature and drew conclusions, which were discussed and approved in a consensus conference of the Infectious Disease Working Party of the German Society of Hematology and Oncology (AGIHO). Antibacterial prophylaxis has led to a reduction of febrile events and infections. A significant reduction of overall mortality could only be shown in a meta-analysis. Fluoroquinolones are preferred for antibacterial and trimethoprim-sulfamethoxazole for PCP prophylaxis. Due to serious concerns about an increase of resistant pathogens, only patients at high risk of severe infections should be considered for antibiotic prophylaxis. Risk factors of individual patients and local resistance patterns must be taken into account. Risk factors, choice of drug for antibacterial and PCP prophylaxis and concerns regarding the use of prophylactic antibiotics are discussed in the review.
Comment in
-
Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines.Ann Hematol. 2013 Nov;92(11):1569-70. doi: 10.1007/s00277-013-1743-z. Epub 2013 Apr 5. Ann Hematol. 2013. PMID: 23558908 No abstract available.
Similar articles
-
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).Ann Hematol. 2021 Jun;100(6):1603-1620. doi: 10.1007/s00277-021-04452-9. Epub 2021 Apr 13. Ann Hematol. 2021. PMID: 33846857 Free PMC article.
-
Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).Ann Hematol. 2021 Feb;100(2):321-336. doi: 10.1007/s00277-020-04297-8. Epub 2020 Oct 20. Ann Hematol. 2021. PMID: 33079221 Free PMC article. Review.
-
Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines.Ann Hematol. 2013 Nov;92(11):1569-70. doi: 10.1007/s00277-013-1743-z. Epub 2013 Apr 5. Ann Hematol. 2013. PMID: 23558908 No abstract available.
-
Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Ann Hematol. 2012 Aug;91(8):1161-74. doi: 10.1007/s00277-012-1456-8. Epub 2012 May 26. Ann Hematol. 2012. PMID: 22638755 Review.
-
Guidelines for the Prophylaxis of Pneumocystis jirovecii Pneumonia (PJP) in Children With Solid Tumors.J Pediatr Hematol Oncol. 2017 Apr;39(3):194-202. doi: 10.1097/MPH.0000000000000771. J Pediatr Hematol Oncol. 2017. PMID: 28267082
Cited by
-
Pneumocystis jirovecii pneumonia in non-HIV patients: need for a more extended prophylaxis.Front Med (Lausanne). 2024 Jun 26;11:1414092. doi: 10.3389/fmed.2024.1414092. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38988362 Free PMC article.
-
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.Blood Adv. 2024 Apr 9;8(7):1787-1795. doi: 10.1182/bloodadvances.2023011231. Blood Adv. 2024. PMID: 38592710 Free PMC article. Clinical Trial.
-
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee.Cytotherapy. 2024 Jul;26(7):660-671. doi: 10.1016/j.jcyt.2024.02.005. Epub 2024 Feb 20. Cytotherapy. 2024. PMID: 38483362 Review.
-
Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial.Front Oncol. 2023 Aug 18;13:1142449. doi: 10.3389/fonc.2023.1142449. eCollection 2023. Front Oncol. 2023. PMID: 37664023 Free PMC article.
-
A machine learning diagnostic model for Pneumocystis jirovecii pneumonia in patients with severe pneumonia.Intern Emerg Med. 2023 Sep;18(6):1741-1749. doi: 10.1007/s11739-023-03353-1. Epub 2023 Aug 2. Intern Emerg Med. 2023. PMID: 37530943 Clinical Trial.
References
-
- Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987. doi: 10.1056/NEJMoa044097. - DOI - PubMed
-
- Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, Engelhard D, Marchetti O, Akan H, Skoutelis A, Korten V, Vandercam M, Gaya H, Padmos A, Klastersky J, Zinner S, Glauser MP, Calandra T, Viscoli C, International Antimicrobial Therapy Group of the European Organization for Research Treatment of Cancer Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin–tazobactam monotherapy. Clin Infect Dis. 2003;37:382–389. doi: 10.1086/376637. - DOI - PubMed
-
- Sandherr M, Einsele H, Hebart H, Kahl C, Kern W, Kiehl M, Massenkeil G, Penack O, Schiel X, Schuettrumpf S, Ullmann AJ, Cornely OA, Infectious Diseases Working Party, German Society for Hematology and Oncology Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) Ann Oncol. 2006;17:1051–1059. doi: 10.1093/annonc/mdj132. - DOI - PubMed
-
- Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, Krause SW, Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M, Vehreschild JJ, Wolf HH, Ullmann AJ. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2009;94:113–122. doi: 10.3324/haematol.11665. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical